These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24809953)

  • 21. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
    Sriram D; Aubry A; Yogeeswari P; Fisher LM
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis.
    Zhang YJ; Li XJ; Mi KX
    Yi Chuan; 2016 Oct; 38(10):918-927. PubMed ID: 27806933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
    Suzuki Y; Nakajima C; Tamaru A; Kim H; Matsuba T; Saito H
    Int J Antimicrob Agents; 2012 May; 39(5):435-9. PubMed ID: 22421328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
    Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
    Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
    Kale MG; Raichurkar A; P SH; Waterson D; McKinney D; Manjunatha MR; Kranthi U; Koushik K; Jena Lk; Shinde V; Rudrapatna S; Barde S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Ghosh A; Ramya VK; Guptha S; Sharma S; Vachaspati P; Kumar KN; Giridhar J; Reddy J; Panduga V; Ganguly S; Ahuja V; Gaonkar S; Kumar CN; Ogg D; Tucker JA; Boriack-Sjodin PA; de Sousa SM; Sambandamurthy VK; Ghorpade SR
    J Med Chem; 2013 Nov; 56(21):8834-48. PubMed ID: 24088190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Dec; 113():43-54. PubMed ID: 30514513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Series of Spiropyrimidinetriones that Enhances DNA Cleavage Mediated by
    Byl JAW; Mueller R; Bax B; Basarab GS; Chibale K; Osheroff N
    ACS Infect Dis; 2023 Mar; 9(3):706-715. PubMed ID: 36802491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
    Chaudhari K; Surana S; Jain P; Patel HM
    Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
    Das S; Garg T; Srinivas N; Dasgupta A; Chopra S
    Curr Top Med Chem; 2019; 19(8):579-593. PubMed ID: 30834837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA topoisomerase I and DNA gyrase as targets for TB therapy.
    Nagaraja V; Godbole AA; Henderson SR; Maxwell A
    Drug Discov Today; 2017 Mar; 22(3):510-518. PubMed ID: 27856347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
    Wiles JA; Phadke AS; Bradbury BJ; Pucci MJ; Thanassi JA; Deshpande M
    J Med Chem; 2011 May; 54(9):3418-25. PubMed ID: 21443219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
    Kale RR; Kale MG; Waterson D; Raichurkar A; Hameed SP; Manjunatha MR; Kishore Reddy BK; Malolanarasimhan K; Shinde V; Koushik K; Jena LK; Menasinakai S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sharma S; Nandishaiah R; Mahesh Kumar KN; Ganguly S; Ahuja V; Gaonkar S; Naveen Kumar CN; Ogg D; Boriack-Sjodin PA; Sambandamurthy VK; de Sousa SM; Ghorpade SR
    Bioorg Med Chem Lett; 2014 Feb; 24(3):870-9. PubMed ID: 24405701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
    Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
    Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues.
    Jeankumar VU; Renuka J; Kotagiri S; Saxena S; Kakan SS; Sridevi JP; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
    ChemMedChem; 2014 Aug; 9(8):1850-9. PubMed ID: 24962352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
    Aldred KJ; Blower TR; Kerns RJ; Berger JM; Osheroff N
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E839-46. PubMed ID: 26792518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis.
    Minovski N; Perdih A; Novic M; Solmajer T
    J Comput Chem; 2013 Apr; 34(9):790-801. PubMed ID: 23280926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.
    Rao SP; Lakshminarayana SB; Kondreddi RR; Herve M; Camacho LR; Bifani P; Kalapala SK; Jiricek J; Ma NL; Tan BH; Ng SH; Nanjundappa M; Ravindran S; Seah PG; Thayalan P; Lim SH; Lee BH; Goh A; Barnes WS; Chen Z; Gagaring K; Chatterjee AK; Pethe K; Kuhen K; Walker J; Feng G; Babu S; Zhang L; Blasco F; Beer D; Weaver M; Dartois V; Glynne R; Dick T; Smith PW; Diagana TT; Manjunatha UH
    Sci Transl Med; 2013 Dec; 5(214):214ra168. PubMed ID: 24307692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
    Mayer C; Takiff H
    Microbiol Spectr; 2014 Aug; 2(4):MGM2-0009-2013. PubMed ID: 26104201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
    Mdluli K; Ma Z
    Infect Disord Drug Targets; 2007 Jun; 7(2):159-68. PubMed ID: 17970226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
    Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.